BioRestorative Therapies, Inc.
BRTX
$2.74
-$0.06-2.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 23.20K | 19.60K | 11.80K | 303.30K | 25.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 23.20K | 19.60K | 11.80K | 303.30K | 25.00K |
| Cost of Revenue | 7.40K | 1.60K | 10.60K | 8.70K | 2.90K |
| Gross Profit | 15.80K | 18.00K | 1.20K | 294.60K | 22.10K |
| SG&A Expenses | 1.48M | 1.22M | 1.12M | 1.37M | 2.18M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.41M | 3.84M | 3.72M | 3.61M | 4.83M |
| Operating Income | -3.39M | -3.83M | -3.71M | -3.31M | -4.81M |
| Income Before Tax | -2.15M | -3.21M | -3.04M | -2.66M | -5.34M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.15M | -3.21M | -3.04M | -2.66M | -5.34M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.15M | -3.21M | -3.04M | -2.66M | -5.34M |
| EBIT | -3.39M | -3.83M | -3.71M | -3.31M | -4.81M |
| EBITDA | -3.33M | -3.77M | -3.66M | -3.25M | -4.76M |
| EPS Basic | -2.43 | -6.58 | -6.67 | -6.08 | -12.78 |
| Normalized Basic EPS | -1.52 | -4.11 | -4.17 | -3.80 | -7.99 |
| EPS Diluted | -2.43 | -6.58 | -6.67 | -6.08 | -12.78 |
| Normalized Diluted EPS | -1.52 | -4.11 | -4.17 | -3.80 | -7.99 |
| Average Basic Shares Outstanding | 886.40K | 487.30K | 455.80K | 437.00K | 417.90K |
| Average Diluted Shares Outstanding | 886.40K | 487.30K | 455.80K | 437.00K | 417.90K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |